Keratoacanthoma
☆ AI Dermatology — Free Service
Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Keratoacanthoma biasa
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) mangrupikeun tumor kulit anu sering dikenal kusabab kamekaranna anu gancang sarta poténsial pikeun mundur sorangan. Ieu ilaharna lumangsung dina jalma kolot, lalaki, kulit adil, jeung boga sajarah paparan sinar panonpoé. Panyabutan bedah ku eksisi atawa bedah mikrografi Mohs mangrupikeun perlakuan anu biasa, tapi aya ogé sababaraha pilihan terapi séjén.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) mangrupakeun tumor low‑grade anu dimimitian tina kelenjar khusus di kulit jeung katingalina sarupa squamous cell carcinoma (SCC) dina mikroskop. Masih aya perdebatan ngeunaan naha KA kedah digolongkeun salaku bentuk SCC invasif.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) mangrupikeun jinis kanker kadua anu paling umum di antara jalma, khususna dina kalangan sepuh. Bedah biasana dipaké pikeun ngubaran cSCC, tapi pikeun sababaraha pasien anu teu tiasa dioperasi atawa milih henteu, pilihan séjén sapertos pangobatan intralesional tiasa dipertimbangkeun. Pangobatan intralesional tradisional (methotrexate or 5-fluorouracil) geus dipaké, tapi aya panalungtikan terus‑terusan ngeunaan pendekatan anyar sapertos immunotherapy intralesional jeung virotherapy oncolytic. Dina bagian ieu, urang bakal ngabahas rupa‑rupa perlakuan intralesional pikeun cSCC, ti métode klasik nepi ka strategi canggih.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Dina mikroskop, keratoacanthoma kacida miripna jeung karsinoma sél skuamosa. Nalika sababaraha ahli patologi ngagolongkeun keratoacanthoma salaku éntitas anu béda sareng henteu ganas, sakitar 6 % kasus klinis jeung histologisna tiasa mekar jadi kanker sél skuamosa invasif jeung agrésif.
○ Diagnosis sareng Perawatan
#Dermoscopy
#Skin biopsy